Hamilton Named Key Partner in Ontario’s Nuclear Innovation & Radiopharmaceutical Expansion

Today’s provincial announcement at AtomVie Global Radiopharma Inc., located right here in Ward 11, marks an important milestone for Hamilton’s growing medical-innovation sector and for Ontario’s expanding leadership in nuclear technologies.

While full details of the provincial contribution are expected to be confirmed, the Province signaled support for expanding radiopharmaceutical and medical-isotope production capacity in Ontario - an area where Hamilton is already a recognized leader.

Hamilton: A Powerhouse in Innovation

Hamilton - and Ward 11 in particular - continues to demonstrate that we are ready to answer the call. With world-class institutions, a highly skilled workforce, and a thriving biomedical and nuclear-medicine ecosystem, our city plays a central role in advancing health research and manufacturing.

Companies like AtomVie, internationally recognized for excellence in radiopharmaceutical production, strengthen this ecosystem. Their work attracts investment, advances cutting-edge research, and supports high-quality jobs in Hamilton and across Ontario. AtomVie’s expansion builds on its position as a global contract-development and manufacturing leader - one capable of scaling the production of life-saving radiopharmaceuticals for clinical and commercial use.

Advancing Therapies and Improving Outcomes

Ontario’s growing nuclear-medicine leadership is translating directly into:

• improved access to life-saving therapies

• advanced treatment options closer to home

• faster pathways from research to clinical use

• greater stability in the global isotope supply

As production capacity increases - and as new radiopharmaceutical technologies continue to show promising results - patients stand to benefit from faster diagnostics, precision cancer treatments, and better long-term health outcomes.

A Strong Voice at the Table

Today’s announcement reflects Ontario’s confidence in Hamilton’s role as a partner in radiopharmaceutical manufacturing and research. Combined with the city’s innovation strengths, this investment ensures Hamilton continues to have a strong voice at the table as next-generation health technologies emerge.

A Made-in-Canada Advantage

This work represents a significant “made-in-Canada” advantage: ensuring that the development, production, and distribution of critical medical isotopes takes place in Canada, supporting domestic expertise, supply-chain resilience, and long-term economic growth.

I'm pleased to see this kind of investment in Hamilton, and Ward 11.